ASCO 2023 Prostate Cancer - Results from #60

Viewing 61-80 of 84 articles

ASCO 2023: A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE): A Trial in Progress

ASCO 2023: GUIDE: A Randomized Non-Comparative Phase II Trial of Biomarker-Driven Intermittent Docetaxel Versus Standard-of-Care Docetaxel in Metastatic Castration-Resistant Prostate Cancer (ANZUP 1903)

ASCO 2023: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy: Updated Individual Patient Data Meta-Analyses from the MARCAP Consortium

ASCO 2023: Basal-Luminal Subtyping of Localized High-Risk Prostate Cancer and Benefit of Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase III Trial

ASCO 2023: Post Radical Prostatectomy PSA Outcomes Following 6 vs 18 Months of Perioperative Androgen Deprivation Therapy in Men with Localized High Risk Prostate Cancer: Results of Part 2 of a Randomized Phase 2 Trial

ASCO 2023: Depth of PSA Nadir and Subsequent PSA Progression-Free Survival in Patients with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19)

ASCO 2023: Assessing Racial Differences in Time to Treatment Escalation Following Androgen-Deprivation Therapy Among Veterans with Prostate Cancer

ASCO 2023: CABIOS Trial: A Phase Ib Study of Cabozantinib and Nivolumab in Combination with Abiraterone in Patients with Metastatic Hormone Sensitive Prostate Cancer

ASCO 2023: Darolutamide Observational (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Second Interim Analysis.

ASCO 2023: Landscape and Impact of Germline Pathogenic Variants in Metastatic Hormone Sensitive Prostate Cancer: Ancillary Study of E3805 CHAARTED

ASCO 2023: Prostate-Specific Antigen Value at 3 & 7 Months (PSA-3mo, PSA-7mo) and Overall Survival (OS) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation (ADT) with or without Orteronel (SWOG S1216)

ASCO 2023: Enzalutamide, Docetaxel and Androgen Deprivation (ENZADA Trial) for Metastatic Castrate Sensitive Prostate Cancer

ASCO 2023: Circulating Tumor Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Treated with Olaparib plus 177lutetium-Prostate Specific Membrane Antigen-617 (177Lu-PSMA-617) in the LuPARP Trial

ASCO 2023: Early Results from CASCARA: A Phase 2 Study of Cabazitaxel/Carboplatin plus Abiraterone in High-Volume Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)

ASCO 2023: Early Changes of PSMA PET Signal After Initiation of Androgen Receptor Signaling Inhibitors in mCRPC: An International Multicenter Retrospective Study

ASCO 2023: Use of ctDNA to Complement Tumor Tissue Homologous Recombination Repair Gene Alteration Testing in TALAPRO-2, a Study of Talazoparib + Enzalutamide Vs Placebo + ENZA as First-Line Treatment for mCRPC

ASCO 2023: Treatment and Survival of De Novo mHSPC Among African American US Veterans

ASCO 2023: PSMA Expression and Response to 177Lu-PSMA-617 in Men with vs. Without DNA Damage Repair Mutations

ASCO 2023: PSMA PET Findings in an “EMBARK-like” Cohort of Patients with High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer: A Single Center Post-Hoc Retrospective Analysis

ASCO 2023: The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mHSPC

1
2
3
4
5